ANZMTG - Australia and New Zealand Melanoma Trials Group Home | Login
ANZMTG - Australia and New Zealand Melanoma Trials Group
 

LOGIN



Please enter your username and password.


Username

Password


  
ANZMTG
 

ANZMTG 02.17 MEL-SELF Trial - Can patient-led surveillance detect more early stage recurrent or new primary melanoma than clinician-led surveillance?

After surgical removal of localised melanoma (Melanoma in situ and stage I/II), most patients have a very good prognosis in terms of life expectancy. They are currently recommended to attend lifelong routinely scheduled clinics for surveillance of recurrence or new primary (clinician-led surveillance).  Patient led surveillance is an alternative model of follow-up which uses teledermatology and fast-tracked clinical review. This clinical trial is a randomised, two-arm, pilot study which aims to compare patient-led surveillance with clinical-led surveillance in patients who have been treated for a stage 0/I/II melanoma. 

 

Study status - In Development

ANZ Clinical Trials Registry # - ACTRN12616001716459
ClinicalTrials.gov identifier - In Progress
 

Principal Investigator's details:
Dr. Katy Bell
The University of Sydney 

ANZMTG coordinator details:

Email: anzmtg02.17@melanoma.org.au
Phone: +61 2 9911 7294


Return to Previous Page